FGF21 and hepatocellular carcinoma: This could involve clinical trials evaluating FGF21 as a biomarker for MASLD severity, guiding analog dosing to prevent HCC in high-risk patients, and using miR-22-3p for stratifying those with metabolic reprogramming to enable targeted miRNA therapies in glycolytic-dominant HCC.